UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) **November 15, 2004**

ADVENTRX Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

001-32157	**84-1318182**
(Commission File Number)	(IRS Employer Identification No.)

6725 Mesa Ridge Road, Suite 100
San Diego, California 92121
(Address of principal executive offices) (Zip Code)

(858) 552-0866
(Company's telephone number, including area code)

Item 2.02. Results of Operations and Financial Condition.

On November 15, 2004, ADVENTRX Pharmaceuticals, Inc. issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2004. A copy of this press release is furnished as Exhibit 99.1 to this report and is incorporated into this Form 8-K by reference.

Item 9.01. Financial Statements and Exhibits.

(c) The exhibit list required by this item is incorporated by reference to the Exhibit Index filed as part of this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ADVENTRX Pharmaceuticals, Inc.

By: /s/ Steven M. Plumb

Name: Steven M. Plumb, CPA
Title: Chief Financial Officer

November 15, 2004

EXHIBIT INDEX

Exhibit	Description
99.1	Press Release of the Company dated November 15, 2004.

ADVENTRX Pharmaceuticals Announces Third Quarter 2004 Results

SAN DIEGO, November 15, 2004 - ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX) announced results today for the third quarter ended September 30, 2004.

The Company reported a net loss of $2,123,807, or $0.04 per share, for the three months ended September 30, 2004. This compares to a net loss of $494,927, or $0.02 per share, for the three months ended September 30, 2003.

Research and development expenses for the three months ended September 30, 2004 increased by $774,887 to $983,665 from $208,778 for the same period last year. Cost increases were attributed mainly to expanded research and development, pre-clinical efforts and clinical trial operations for our CoFactor™, BlockAide/CR™, Thiovir™ and EradicAide™ products.

General and administrative expenses for the three months ended September 30, 2004 increased by $878,468 to $1,155,716 from $277,248 for the same period last year. The increase was primarily due to higher costs associated with the Company's new facility, higher legal and profe ssional fees and expenses and increased payroll expense primarily attributable to an increase in the number of employees from 4 employees at September 30, 2003 to 10 employees at September 30, 2004.

"The 3rd quarter saw continued progress for our CoFactor clinical program, through the addition of European sites which will allow us to reach our enrollment objectives more quickly," said Evan M. Levine, President and CEO. "Furthermore, we have continued to expand our research and development staff and broaden our research and development activities since our move to a larger facility with laboratories in place."

About ADVENTRX

ADVENTRX Pharmaceuticals, Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses on cancer and viral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. More information can be found on the Company's website at www.adventrx.com.

Forward Looking Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the United States Food and Drug Administration and other regulatory agencies. The Company undertakes no obligation to release publicly any r evisions, which may be made to reflect events or circumstances after the date hereof.

Contact:
ADVENTRX Pharmaceuticals
Andrea Lynn
858-552-0866